Public Profile

Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd., commonly referred to as Glenmark, is a prominent global player in the pharmaceutical industry, headquartered in India. Founded in 1977, the company has established a strong presence in various operational regions, including North America, Europe, and emerging markets. Glenmark focuses on the development and manufacturing of innovative generics, specialty pharmaceuticals, and over-the-counter products. With a diverse portfolio that includes formulations in therapeutic areas such as dermatology, oncology, and respiratory, Glenmark is recognised for its commitment to research and development. The company has achieved significant milestones, including numerous product approvals and a robust pipeline of new therapies. Glenmark's dedication to quality and innovation has positioned it as a trusted name in the pharmaceutical sector, making notable strides in both domestic and international markets.

DitchCarbon Score

How does Glenmark Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

61

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Glenmark Pharmaceuticals's score of 61 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.

96%

Let us know if this data was useful to you

Glenmark Pharmaceuticals's reported carbon emissions

In 2023, Glenmark Pharmaceuticals reported total greenhouse gas emissions of approximately 175,069,000 kg CO2e across all scopes. This includes about 12,703,000 kg CO2e from Scope 1, which encompasses direct emissions from owned or controlled sources, and approximately 64,812,000 kg CO2e from Scope 2, related to indirect emissions from the generation of purchased electricity. The company also reported significant Scope 3 emissions, totalling around 175,069,000 kg CO2e, which includes emissions from the supply chain and product use. Glenmark has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 35% by FY2035, using FY2021 as the baseline year. Additionally, the company targets a 28% reduction in Scope 3 emissions per ton of pharmaceutical products over the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to global efforts to limit temperature rise to well below 2°C. The company has demonstrated a commitment to sustainability through these initiatives, reflecting its responsibility towards reducing its carbon footprint and addressing climate change challenges in the pharmaceutical industry.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20202021202220232024
Scope 1
11,713,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
74,231,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
3,277,000
000,000,000
000,000,000
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Glenmark Pharmaceuticals's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Glenmark Pharmaceuticals is in IN, which has a very high grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Glenmark Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Abbott India Limited

IN
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Emcure

IN
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Ajanta Pharma

IN
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Lupin

IN
Pharmaceutical Preparation Manufacturing
Updated about 14 hours ago

Merck And Co

US
Pharmaceutical Preparation Manufacturing
Updated about 15 hours ago

Intas

IN
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers